HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


FDA Decision Has Plan B Headed For Behind-The-Counter Sale

This article was originally published in The Tan Sheet

Executive Summary

FDA appears to be ready to create a third class of drugs

You may also be interested in...

Barr Has No Plan B Plans For Broad DTC Campaign

Barr is running an advertising campaign in college newspapers for its Plan B emergency contraceptive while the company awaits FDA's decision on an OTC switch of the drug

Crawford Nomination Woes Grow With Coburn Hold, Hager Letter

FDA Acting Commissioner Lester Crawford's bid for the permanent post has been cast further into doubt by a Republican joining the list of Senators threatening holds on his nomination

Fate Of Plan B, Crawford’s FDA Confirmation May Be Decided This Month

An FDA announcement on Barr's Plan B emergency contraceptive could be two weeks away now that a confirmation vote on FDA Acting Commissioner Lester Crawford is slated for later this month

Related Content





Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts